Could a common diabetes pill protect new Moms' hearts?
NCT ID NCT06785116
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if dapagliflozin, a diabetes drug, can reduce heart and blood vessel risks in women who had high blood pressure during pregnancy. About 200 participants will take either the drug or a placebo daily for six months after delivery. The goal is to see if the drug improves blood pressure, weight, and heart function, potentially preventing future heart problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR COMPLICATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan
RECRUITINGAnn Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a heart drug be a new key to controlling high blood pressure?
- Can tighter blood pressure control in pregnancy prevent serious complications?
- A simple arm cuff may lower blood pressure without drugs
- Tiny particles in the blood may warn of dangerous pregnancy high blood pressure
- Home visits may boost heart health for pregnant women in nigeria
- Postpartum blood pressure control may stop preeclampsia from leading to lifelong hypertension